Pfizer reports topline data from SigVie-002 study for NSCLC

Pfizer has reported topline data from the Phase III SigVie-002 study investigating sigvotatug vedotin in adults with previously treated, locally advanced or metastatic non-squamous NSCLC. The trial enrolled 703 participants who had previously received one or more lines of systemic therapy. The study’s primary endpoint was OS, with PFS, ORR, and DOR as descriptive secondary endpoints. Credit: PeopleImages / Shutterstock.com. Pfizer has reported topline data from the Phase III SigVie-002 study investigating sigvotatug vedotin in adults with previously treated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). The investigational integrin beta-6 (IB6)-targeted antibody-drug conjugate (ADC) did not achieve…

Source: Clinical Trials Arena